Advisory Services Network LLC Trims Holdings in AbbVie Inc. $ABBV

Advisory Services Network LLC lessened its holdings in AbbVie Inc. (NYSE:ABBV) by 8.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 125,303 shares of the company’s stock after selling 11,778 shares during the quarter. AbbVie comprises approximately 0.4% of Advisory Services Network LLC’s investment portfolio, making the stock its 29th largest holding. Advisory Services Network LLC’s holdings in AbbVie were worth $29,012,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie during the 2nd quarter worth about $26,000. Texas Capital Bancshares Inc TX purchased a new position in shares of AbbVie in the 3rd quarter valued at about $31,000. Caitlin John LLC acquired a new position in AbbVie in the 3rd quarter worth about $33,000. Delos Wealth Advisors LLC purchased a new position in AbbVie during the second quarter worth approximately $39,000. Finally, Redmont Wealth Advisors LLC purchased a new position in AbbVie during the third quarter worth approximately $41,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.08% of the company’s stock.

Analyst Ratings Changes

ABBV has been the topic of a number of research analyst reports. Citigroup dropped their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. Barclays began coverage on shares of AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective on the stock. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research report on Tuesday, January 20th. Piper Sandler boosted their target price on shares of AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Finally, Guggenheim reaffirmed a “buy” rating on shares of AbbVie in a research note on Thursday, March 12th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Price Performance

ABBV stock opened at $219.96 on Wednesday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm has a market capitalization of $388.92 billion, a PE ratio of 93.20, a price-to-earnings-growth ratio of 0.77 and a beta of 0.34. The business has a 50 day simple moving average of $224.27 and a 200-day simple moving average of $224.95.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s revenue was up 10.0% compared to the same quarter last year. During the same period last year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. AbbVie’s payout ratio is 293.22%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Alloy Therapeutics signed a multi‑year agreement with AbbVie to develop a next‑generation antibody discovery platform; Alloy will receive an upfront payment plus milestones, which can accelerate discovery of hard‑to‑drug targets and provide non‑dilutive near‑term cash. Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
• Positive Sentiment: William Blair reiterated confidence in AbbVie’s growth prospects tied to obesity treatment progress after positive Phase 1 results — this underscores potential upside from a new high‑growth therapeutic area beyond core franchises. William Blair Asserts AbbVie Inc. (ABBV) Growth Prospects on Obesity Treatment Opportunities
• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) launched a Skin Quality Index to standardize patient/provider conversations in aesthetics — a marketing and product‑positioning move that can support elective‑procedure demand and cross‑sell across Allergan’s portfolio. AbbVie’s Skin Quality Index Aims To Shape Aesthetics Growth Narrative
• Positive Sentiment: Notable institutional interest: Billionaire Ken Fisher’s fund has included AbbVie among its notable 2026 moves, signaling confidence from an established investor and potential buying support. AbbVie Inc. (ABBV): Billionaire Ken Fisher Admires This Pharma Stock
• Neutral Sentiment: Zacks and other analysts highlight AbbVie as a strong value stock based on valuation metrics and steady cash flows — useful context for longer‑term investors but not an immediate price catalyst. Here’s Why AbbVie (ABBV) is a Strong Value Stock
• Neutral Sentiment: A U.S. appeals court revived a whistleblower lawsuit alleging overcharging on drugs for low‑income patients against several large drugmakers, creating a sector‑level legal overhang; it’s unclear from published reports whether AbbVie is a named defendant, but the ruling increases regulatory/legal risk for big pharma generally. Big drugmakers must face US overcharge claims on medications for low-income patients
• Negative Sentiment: Technical pressure — several market writeups note ABBV has slipped below its 50‑day simple moving average, signaling short‑term momentum weakness and prompting traders to take profits or wait for a dip to re‑enter. AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.